BML, Inc. (MUN:BMZ)

Market Cap	757.06M -3.9%
Revenue (ttm)	814.60M +3.9%
Net Income	42.36M +22.6%
EPS	1.12 +26.8%
Shares Out	n/a
PE Ratio	17.87
Forward PE	n/a
Dividend	0.70 (3.47%)
Ex-Dividend Date	Sep 29, 2026

Volume	n/a
Open	20.20
Previous Close	20.40
Day's Range	20.20 - 20.20
52-Week Range	18.40 - 23.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to ...

• Industry: Commercial Physical and Biological Research
• Founded: 1955
• Employees: 4,612
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: BMZ

Financial Performance

In fiscal year 2026, BML, Inc.'s revenue was 150.26 billion, an increase of 4.94% compared to the previous year's 143.19 billion. Earnings were 7.75 billion, an increase of 23.71%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 8, 2026

Data Sources Report a data error